Olaf van Tellingen

This study evaluates the efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma in vitro and in vivo, finding strong in vitro activity but no antitumor effect in mouse models.

This study investigates how CSF1R inhibition during cranial radiotherapy affects the brain's immune environment and glial dynamics, showing sustained microglial loss and monocyte replacement.

This study shows that high-dose CSF1R inhibitors pexidartinib and sotuletinib rapidly deplete microglia despite limited brain penetration, with significant off-target effects on other immune and tissue cells.

The paper shows that mitochondrial damage can induce therapy-induced senescence in GBM cells through a ROS-cGAS-STING-SASP cascade, outperforming single or dual pathway inhibitors.